ALMR — Alamar Biosciences, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 2104204 ·
Last close
$25.36
Market Cap
$1.76B
52W High
$29.43
52W Low
$18.85
ADV30
362,411
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 26,035,000 | 14,457,000 | -12,347,000 | -21,325,000 | 186,451,000 | 64,586,000 | 364,522,000 |
| Mar 2025 | 13,091,000 | 6,389,000 | -8,553,000 | -7,659,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,415,000
Investing CF
$16,240,000
Financing CF
$56,004,000
CapEx
$-1,760,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-05-20
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$87,155,000
EBITDA
$-32,085,000
Free Cash Flow
—
Enterprise Value
$2,013,590,400
Total Cash
$64,586,000
Total Debt
$105,549,000
Shares Out
69,311,186
Trailing EPS
$-0.65
Book Value
$-2.57
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 74,211,000 | -31,334,000 | -29,819,000 | 139,992,000 | 298,946,000 | — | -53,608,000 |
| Dec 2024 | 25,142,000 | -49,568,000 | -47,073,000 | 149,511,000 | 282,922,000 | — | -55,214,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.70
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JHPCY | Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR | $1.76B | $13.60 | — |
| GDV-PH | GABELLI DIVIDEND & INCOME TRUST | $1.75B | $21.27 | — |
| ASTH | Astrana Health, Inc. | $1.76B | $35.56 | — |
| EYE | National Vision Holdings, Inc. | $1.77B | $22.04 | — |
| GAB | GABELLI EQUITY TRUST INC | $1.75B | $5.61 | — |
News headlines (Yahoo Finance, 1h cache)
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
2026-07-28 20:12 · Yahoo
ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
2026-07-23 12:30 · Yahoo
Braveheart, Attovia join next wave of biotech IPOs
2026-07-15 11:34 · Yahoo
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
2026-07-14 20:05 · Yahoo
Alamar Hits A High Note On Alzheimer's Buzz
2026-07-13 20:50 · Yahoo
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
2026-07-13 06:30 · Yahoo
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
2026-07-10 10:11 · Yahoo
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
2026-07-07 13:12 · Yahoo
Cathie Wood Doubles Down on AI, Loads Up on Tesla, Palantir, and SpaceX
2026-07-01 13:04 · Yahoo
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
2026-06-23 15:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.